Yifeng Pharmacy (603939) — Strategic Asset Allocation Index
Yifeng Pharmacy (603939) has a Strategic Asset Allocation Index of 52.4% as of June 2023. Strategic assets (PP&E of CN¥5.13 Billion plus long-term investments of CN¥-) total CN¥5.13 Billion, measured against net assets of CN¥9.80 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See 603939 net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Yifeng Pharmacy Strategic Asset Allocation Index (2011–2022)
This chart shows how Yifeng Pharmacy's Strategic Asset Allocation Index has evolved across 12 annual periods from 2011 to 2022. As of June 2023, the index stands at 52.4%, representing strategic assets of CN¥5.13 Billion against net assets of CN¥9.80 Billion CNY. For live market cap and overall valuation, see Yifeng Pharmacy market capitalisation.
Annual Strategic Asset Allocation Index for Yifeng Pharmacy (2011–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Yifeng Pharmacy from 2011 to 2022, covering 12 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Yifeng Pharmacy (603939) shareholders funds for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 53.6% | CN¥4.89 Billion | CN¥4.89 Billion | CN¥- | CN¥9.12 Billion | ▼ -3.6 pp |
| 2021 | 57.3% | CN¥4.50 Billion | CN¥4.50 Billion | CN¥- | CN¥7.86 Billion | ▼ -4.1 pp |
| 2020 | 61.4% | CN¥3.55 Billion | CN¥3.55 Billion | CN¥- | CN¥5.78 Billion | ▲ +50.2 pp |
| 2019 | 11.2% | CN¥527.95 Million | CN¥527.95 Million | CN¥- | CN¥4.71 Billion | ▲ +0.5 pp |
| 2018 | 10.7% | CN¥446.13 Million | CN¥416.58 Million | CN¥29.55 Million | CN¥4.17 Billion | ▼ -1.2 pp |
| 2017 | 11.9% | CN¥376.86 Million | CN¥315.21 Million | CN¥61.65 Million | CN¥3.18 Billion | ▲ +1.7 pp |
| 2016 | 10.2% | CN¥303.20 Million | CN¥302.75 Million | CN¥450.00K | CN¥2.98 Billion | ▼ -8.5 pp |
| 2015 | 18.7% | CN¥265.90 Million | CN¥265.45 Million | CN¥450.00K | CN¥1.42 Billion | ▼ -9.1 pp |
| 2014 | 27.8% | CN¥165.62 Million | CN¥165.62 Million | CN¥- | CN¥595.76 Million | ▼ -2.1 pp |
| 2013 | 29.9% | CN¥150.32 Million | CN¥150.32 Million | CN¥- | CN¥502.20 Million | ▼ -4.6 pp |
| 2012 | 34.5% | CN¥146.97 Million | CN¥146.97 Million | CN¥- | CN¥425.82 Million | ▲ +10.7 pp |
| 2011 | 23.8% | CN¥84.70 Million | CN¥84.70 Million | CN¥- | CN¥356.28 Million | — |